29 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250928521193/en/ENHERTU-Demonstrated-Highly-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Invasive-Disease-Free-Survival-Versus-T-DM1-in-DESTINY-Breast05-Phase-3-Trial-in-Patients-with-High-Risk-Early-Breast-Cancer-Following-Neoadjuvant-Therapy
09 Dec 2023
// BUSINESSWIRE
https://www.businesswire.com/news/home/20231208002957/en/Genentech%E2%80%99s-Kadcyla-Is-the-First-Targeted-Therapy-to-Show-Significant-Overall-Survival-Benefit-in-People-With-HER2-Positive-Early-Stage-Breast-Cancer-With-Residual-Invasive-Disease-After-Neoadjuvant-Treatment
17 Aug 2023
// BUSINESSWIRE
07 Dec 2022
// BUSINESSWIRE
07 Dec 2022
// BUSINESSWIRE
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427